Table 3.

Summary of detecting EGFR-activating mutations from plasma DNA

		Plasma DNA
		Mutation	No Mutation
Tumor tissue
Mutation	30	21	9
No mutation	13	2	11
Not available	11	6	5
Response to prior EGFR TKI therapy
Partial response	28	23	5
Stable disease	14	4	10
Progressive disease	8	2	6
Untreated	4	0	4

NOTE: NSCLC patients broken down based on known tumor EGFR mutations and based on clinical outcome with prior EGFR TKI therapy.